X4 Pharmaceuticals (XFOR) Study Update summary
Event summary combining transcript, slides, and related documents.
Study Update summary
8 Jul, 2026Background and Unmet Need in Chronic Neutropenia
Chronic neutropenia affects about 50,000 patients in the U.S., with over 15,000 experiencing recurrent infections despite current treatments.
G-CSF is the only approved therapy but is associated with injection discomfort, bone pain, and long-term risks such as myelodysplasia and leukemia.
There is a significant need for an effective, well-tolerated oral therapy to improve quality of life and reduce infection risk.
Mavorixafor Mechanism and Prior Data
Mavorixafor is an oral CXCR4 antagonist that mobilizes neutrophils from bone marrow to circulation.
Previous studies in WHIM syndrome showed mavorixafor increased ANC by ~600 cells/μL and reduced infection rates by ~60%.
FDA approval for mavorixafor in WHIM syndrome supports its safety and efficacy profile.
Phase 2 Interim Study Design and Objectives
Open-label, six-month trial with 23 participants across monotherapy and combination (with G-CSF) arms.
Main objectives: assess durable ANC increase, benefit in severe CN, and safety/tolerability.
Participants included idiopathic, autoimmune, and congenital CN subtypes.
The study also evaluated durability of response and efficacy in severe CN patients (baseline ANC <500 cells/μL).
Latest events from X4 Pharmaceuticals
- 4WARD data expected in early 2028; 4STEPS will test G-CSF dose reduction.XFOR
Jefferies Global Healthcare Conference - 4WARD enrollment targets year-end 2026, with topline data expected in Q1 2028.XFOR
Stifel 2026 Healthcare Conference 2026 - 4WARD enrollment is targeted for year-end 2026; top-line results are expected in Q1 2028.XFOR
3rd Annual Guggenheim Healthcare Innovation Conference - Higher product sales and 4WARD progress accompany debt refinancing and runway into Q1 2029.XFOR
Q3 2026 - Mavorixafor’s PCN opportunity pairs a ~15,000-patient base with Q1 2028 readouts.XFOR
Investor Day 2026 - 4WARD topline data are expected in H1 2028, backed by Phase 2 evidence of ANC gains and reduced G-CSF use.XFOR
Corporate presentation - Phase III enrollment nears completion, with launch targeted for late 2028 or early 2029.XFOR
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue was $8.8M, net loss improved, and cash runway extends into 2029.XFOR
Q2 2026 - Q2 net income hit $90.8M on $105M PRV sale and XOLREMDI U.S. launch.XFOR
Q2 2024